Logo image of PTIX

PROTAGENIC THERAPEUTICS INC (PTIX) Stock Price, Quote, News and Overview

NASDAQ:PTIX - Nasdaq - US74365N2027 - Common Stock - Currency: USD

0.2655  +0.01 (+2.12%)

After market: 0.2654 0 (-0.04%)

PTIX Quote, Performance and Key Statistics

PROTAGENIC THERAPEUTICS INC

NASDAQ:PTIX (2/21/2025, 8:00:01 PM)

After market: 0.2654 0 (-0.04%)

0.2655

+0.01 (+2.12%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.87
52 Week Low0.25
Market Cap1.92M
Shares7.24M
Float6.27M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-31 2025-03-31
IPO12-18 1996-12-18


PTIX short term performance overview.The bars show the price performance of PTIX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

PTIX long term performance overview.The bars show the price performance of PTIX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PTIX is 0.2655 USD. In the past month the price decreased by -36.79%. In the past year, price decreased by -70.05%.

PROTAGENIC THERAPEUTICS INC / PTIX Daily stock chart

PTIX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About PTIX

Company Profile

PTIX logo image Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). The company operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.

Company Info

PROTAGENIC THERAPEUTICS INC

149 Fifth Avenue, Suite 500

New York City NEW YORK 10010 US

CEO: Garo H. Armen

Employees: 2

Company Website: https://protagenic.com/

Investor Relations: https://protagenic.com/investor/sec-filings/

Phone: 12129948200

PROTAGENIC THERAPEUTICS INC / PTIX FAQ

What is the stock price of PROTAGENIC THERAPEUTICS INC today?

The current stock price of PTIX is 0.2655 USD. The price increased by 2.12% in the last trading session.


What is the ticker symbol for PROTAGENIC THERAPEUTICS INC stock?

The exchange symbol of PROTAGENIC THERAPEUTICS INC is PTIX and it is listed on the Nasdaq exchange.


On which exchange is PTIX stock listed?

PTIX stock is listed on the Nasdaq exchange.


What is PROTAGENIC THERAPEUTICS INC worth?

PROTAGENIC THERAPEUTICS INC (PTIX) has a market capitalization of 1.92M USD. This makes PTIX a Nano Cap stock.


How many employees does PROTAGENIC THERAPEUTICS INC have?

PROTAGENIC THERAPEUTICS INC (PTIX) currently has 2 employees.


What are the support and resistance levels for PROTAGENIC THERAPEUTICS INC (PTIX) stock?

PROTAGENIC THERAPEUTICS INC (PTIX) has a resistance level at 0.28. Check the full technical report for a detailed analysis of PTIX support and resistance levels.


Should I buy PROTAGENIC THERAPEUTICS INC (PTIX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PROTAGENIC THERAPEUTICS INC (PTIX) stock pay dividends?

PTIX does not pay a dividend.


When does PROTAGENIC THERAPEUTICS INC (PTIX) report earnings?

PROTAGENIC THERAPEUTICS INC (PTIX) will report earnings on 2025-03-31.


What is the Price/Earnings (PE) ratio of PROTAGENIC THERAPEUTICS INC (PTIX)?

PROTAGENIC THERAPEUTICS INC (PTIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.27).


What is the Short Interest ratio of PROTAGENIC THERAPEUTICS INC (PTIX) stock?

The outstanding short interest for PROTAGENIC THERAPEUTICS INC (PTIX) is 0.72% of its float. Check the ownership tab for more information on the PTIX short interest.


PTIX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PTIX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to PTIX. PTIX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PTIX Financial Highlights

Over the last trailing twelve months PTIX reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS decreased by -39.55% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -374.44%
ROE -785.49%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%56.13%
Sales Q2Q%N/A
EPS 1Y (TTM)-39.55%
Revenue 1Y (TTM)N/A

PTIX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to PTIX. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners8.95%
Ins Owners20.65%
Short Float %0.72%
Short Ratio0.11
Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A